|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study显示文摘BACKGROUND: Some factors have been reported to besassociated with a greater likelihood of sustained viral re-sponse ( SVR) in the interferon (IFN) treatment of chronichepatitis C. The factors include HCV genotype, HCVRNA level in serum, state of liver disease, baseline bodyweight, age, sex, and race. The aim of this trial was to in-vestigate the influence of HCV genotype on the IFN treat-ment of patients with chronic hepatitis C.METHODS: The genotypes of HCV virus were determinedin the patients with chronic hepatitis C from several hospi-tals of China enrolled into the randomized, opened andcontrolled trial of Peg-IFN alpha-2a (pegasys) treatment,controlled with IFN-α-2a (roferon-A). The serum ALTlevels and HCV RNA concentrations of the patients weredetected before and at the end of treatment and during thefollow-up. The influence of HCV genotype on the IFNtreatment of patients with chronic hepatitis C was analyzedin intention-to-treat (ITT) population.RESULTS: The HCV genotypes of 202 patients were deter-mined. Of these patients, 158(78.22%) were infected withgenotype 1 HCV and 44(21.78%) with genotype non-1.The viral response at the end of treatment (ETVR) andsustained viral response (SVR) rates were 53.80% and25.32% respectively in patients with genotype 1 HCV, butthey were 61.36% and 43.18% in patients with genotypenon-1. The difference of SVR between patients with geno-type 1 HCV and those with genotype non-1 was significant(P =0.021). After being grouped by the used drugs, theETVR rates of patients infected with genotype 1 and non-1HCV were 76.83% and 80.95% in the patients treated withpegasys (P =0.686); but their SVR rates were 35.37% and66.67% (P =0. 01). The viral relapse rate of genotype 1HCV (55.56%) was significantly higher than that of geno-type non-1 HCV (23.53%) (P=0.02). In roferon-A group,the ETVR and SVR rates of patients with genotype 1 HCVwere 28.95% and 14.47% respectively, which were lowerbut not more significant than those of patients with geno-type non-1 HCV (43.48% and 21.74%). Moreover, the vi-ral relapse rate of genotype 1 HCV (72.73%) was higherbut not more significant than that of genotype non-1 HCV(50.00%) (P=0.21).CONCLUSION: HCV genotype could affect the efficacies,mainly sustained responses, of IFN treatment in patientswith chronic hepatitis C, and the effects of IFN are relatedto drugs and therapeutic course. | Yao Xie, Dao-Zhen Xu, Zhi-Meng Lu, Kang-Xian Luo, Ji-Dong Jia, Yu-Ming Wang,Gui-Zhen Zhao, Shu-Lin Zhang and Da-Zhi Zhang Department of Infeetious Diseases , Beijing Ditan Hos-pital, Beijing 100011 , China Department of Infec-tious Diseases, Ruijin Hospital, Shanghai 200025, China De-partment of Infectious Diseases, Naifang Hospital, First Military Medical U-niversity, Guangzhou 510515, China (Luo KX) Center of Liver Disease,Beijing Friendship Hospital, Beijing 100050, China (Jia J D ) Institute ofInfectious Disease, Southwest Hospital, Third Military Medical University,Chongqing 410032, China Department of Infectious Disea-ses, Second Hospital, China Medical University, Shenyang 110004, China Department of Infectious Diseases, First Hospital, Xi’ an Jiao-tong University, Xi’ an 710061 , China ) Liver Disease Centerof Chongqing, Second Hospital, Chongqing Medical University,Chongqing 410010, China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，3： | 2 |
| 2 | Quality control measures for lowering the seroconversion rate of hemodialysis patients with hepatitis B or C virus显示文摘BACKGROUND: Hemodialysis (HD) patients are at high risk of infection by hepatitis B virus (HBV) or hepatitis C virus (HCV). The present study was designed to determine the impact of quality control measures on the prevention of transmission of blood-borne viruses. METHODS: A total of 6182 adult maintenance HD patients from all HD units in Zhejiang Province were recruited on January 1, 2007. The baseline demographic and clinical characteristics were recorded and all patients were followed up until death or survival at 4 years later. The Quality Control Standards of Hemodialysis were gradually implemented in HD units. The HBV or HCV seroconversion rates of the recruited patients were calculated and compared every year during the observation period. RESULTS: The prevalence of HBV was 8.3% at the beginning of the study, and 6.6% for HCV. With the implementation of the HD quality control measures, the HBV seroconversion rate tended to decrease year by year (χ 2 =6.620, P=0.085), and the HCV seroconversion rate decreased significantly (χ 2 =10.41, P=0.015). Compared with the data in 2007, the HBV seroconversion rate (χ 2 =4.204, P=0.040, relative risk ratio 0.393, 95% CI 0.156-0.991) and the HCV seroconversion rate (χ 2 =7.373, P=0.007, relative risk ratio 0.386, 95% CI 0.189-0.787) decreased significantly in 2010. CONCLUSION: Quality control measures for HD decreased the seroconversion rates of HBV or HCV in HD patients, showing that updated quality control measures reduce the risk for transmission of blood-borne viruses in the HD population. | Jing Yuan,Yi Yang, Fei Han, Ping Zhang, Xiao-Ying Du, Hua Jiang and Jiang-Hua Chen The Kidney Disease Center, First Affiliated Hospital, Zhejiang University School of Medicine (Yuan J, Yang Y, Han F, Zhang P, Du XY, Jiang H and Chen JH) and Hemodialysis Quality Control Center of Zhejiang Province (Yuan J, Zhang P, Du XY and Chen JH), Hangzhou 310003, China | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，3： | 2 |
| 3 | Updated guidelines for using interferon gamma release assays to detect Mycobacterium turculosis infectiorUnited States, 2010 显示文摘 | Mazurek GH Jereb J Vernon A LoBue P Goldberg S Castro K IGRA Expert Committee Centers for Disease Control and Prevention (CDC) | 2010 | MMWR Recomm Rep2010，59，5： | 1 |
| 4 | International variation in prostate cancer incidence and mortality rates显示文摘 | Center M M Jemal A Lortet - Tieulent J | 2012 | Eur Urol2012，61，6： | 1 |
| 5 | International vari-ation in prostate cancer incidence and mortality rates显示文摘 | Center MM Jemal A Lortet-Tieulent J | 2012 | Eur Urol2012，61，6： | 1 |
| 6 | Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and bodymass index 显示文摘 | NGUYEN T V CENTER J R EISMAN J A | 2000 | J Bone Miner Res2000，10，15： | 1 |
| 7 | The clinical and metabolic effects of rapid weight loss in obese pet cats and the influence of supplemental oral L-carnitine 显示文摘 | Center SA Harte J Watrous D | 2000 | J Vet Intern Med2000，14，6： | 1 |
| 8 | International variation in prostate cancer incidence and mortality rates显示文摘 | Center MM Jemal A Lortet-Tieulent J | 2012 | Eur Urol2012，61，6： | 1 |
| 9 | BMP-4 induces P21 and is associated with apoptosis in the mouse tooth enamel knot显示文摘 | JernvaU J Aberg T Kettunen E The life history of an embryonic signaling center | 1998 | Development1998，125，2： | 1 |
| 10 | Global Cancer Statistics 显示文摘 | Jemal A Bray F Center M M Ferlay J Ward E Forman D | 2011 | CA Cancer J Clin2011，61，： | 1 |
| 11 | queuing systems 显示文摘 | Khazaei H Misic J Misic V: Performance analysis of cloud computing centers using M/G/m/m+r | 2012 | IEEE Trans Parallel Distributed Syst2012，23，： | 1 |
| 12 | Global cancer statistics 显示文摘 | J emal A Bray F Center M M | 2011 | CA Cancer J Clin2011，61，2： | 1 |
| 13 | Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins显示文摘 | Kobe B Center R J Kemp B E | 1999 | Proc Natl Acad Sci USA1999，96，： | 1 |
| 14 | Global cancer statistics 显示文摘 | Jemal A Bray F Center MM Ferlay J | 2011 | CA: A Cancer Journal for Clinicians2011，，61： | 1 |
| 15 | International variation in prostate cancer incidence and mortality rates显示文摘 | Center MM Jemal A Lortet-Tieulent J | 2012 | Eur Urol2012，61，6： | 1 |
| 16 | Dementia family caregiver training: affecting beliefs about caregiving and caregiver outcomes显示文摘 | Hepburn KW Tornatore J Center B | 2001 | J Am Geriatr Soc2001，49，4： | 1 |
| 17 | Utility of the Sindbis replicon system as an Env - targeted HIV vaccine 显示文摘 | Center R J Miller A Wheatley A K | 2013 | Vaccine2013，，： | 1 |
| 18 | International variation in prostate cancer incidence and mortality rates显示文摘 | Center MM Jemal A Lortet Tieulant J | 2012 | Eur Urol2012，61，6： | 1 |
| 19 | A Theoretical, Practical, Predictive Model of Faculty and Department Research Productivity 显示文摘 | BlandC J Center B A Finstad D A | 2005 | Academic Medicine2005，，3： | 1 |
| 20 | Cardiovascular consequences of sleep- disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute 显示文摘 | Quan SF Gersh B J National Center on Sleep Disorders Research | 2004 | Circulation2004，109，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员